Introduction
============

Chronic obstructive pulmonary diseases (COPD) are the fourth leading cause of death in the world, with particularly high prevalence among the elderly population ([@B3]; [@B19]). The diaphragm shows mechanical overloading in COPD, resulting in progressive muscle weakness and compromised diaphragmatic muscle performance ([@B30]; [@B8]; [@B21]). The provision of supplemental oxygen is effective for managing patients' symptoms, but reoxygenation can exacerbate reactive oxygen species (ROS) production, leading to further muscle damage by impairing contractility and accelerating fatigue ([@B8]; [@B47]; [@B50]; [@B59], [@B56]; [@B46]).

In wild-type mice, PO~2~ cycling/hypoxic preconditioning (HPC) exhibits a protective effect on diaphragmatic skeletal muscle by reducing intracellular ROS production during both hypoxia and reoxygenation, as well as improving muscle function ([@B55],[@B56]). It is likely that HPC triggers upstream mediators such as intracellular ROS, phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), and extracellular signal regulated kinase (ERK). HPC also potentially facilitates the opening of mitochondrial ATP-sensitive potassium channels (mitoK~ATP~) and the closure of mitochondrial permeability transition pores (mPTP) ([@B56]). Likewise, in a neonatal hypoxic-ischemic brain injury model, mitoK~ATP~ were involved in HPC-induced neuroprotection, and the administration of a mitoK~ATP~ channel blocker inhibited this protection ([@B49]). In addition, mPTP inhibitor has been shown to reduce ischemia-reperfusion (I/R)-induced skeletal muscle damage ([@B12]). However, the protective effects of HPC and the underlying mechanisms have not been investigated in an aged model of COPD.

Chronic obstructive pulmonary diseases is a late-onset disease primarily found in middle aged and elderly population ([@B34]). It was estimated that 16% of individuals at an age over 65 are affected by COPD. Moreover, COPD that occurs at a later age is linked with significantly reduced quality of life and a higher morbidity ([@B34]). However, there is currently no research that explores the potential benefits of HPC in elderly COPD patients. Therefore, in this study, we aimed to investigate HPC effects in an aged COPD-like mouse model during reoxygenation. We used mice with overexpression of pulmonary tumor necrosis factor-α (TNF-α; Tg^+^) that develop emphysematous alterations ([@B24]; [@B11]). Multiple studies have indicated that TNF-α overexpression is necessary to promote the disease ([@B5]; [@B24]). Elevated expression of pulmonary TNF-α also lead to skeletal muscle dysfunction and increased ROS generation in contracting muscles, as commonly seen in COPD ([@B27]; [@B59]). We hypothesize that HPC attenuates muscle damage during reoxygenation by strengthening the Tg^+^ diaphragm muscle through intracellular signaling cascades that involve ROS and certain mitochondrial channels.

Materials and Methods {#s1}
=====================

Animals and Muscle Strip Preparation
------------------------------------

Adult transgenic mice overexpressing pulmonary TNF-α with the control of surfactant protein (SP)-C were produced by crossing male SP-C/TNF-α Tg^+^ (a generous gift from Dr. I. Mark Olfert, West Virginia University School of Medicine) mice with female C57BL/6 mice followed by PCR screening to confirm genotype ([@B51]; [@B59]). All procedures involving animals were completed in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and the protocol was approved by The Ohio State University Institutional Animal Care and Use Committee. Male Tg^+^ mice aged an average of ∼20 mo (∼20--30 g body weight) were intraperitoneally anesthetized with a mixture of ketamine (80 mg/kg) and xylazine (10 mg/kg). The diaphragm was quickly removed and two muscle strips (∼0.5 cm wide) were dissected out from each leaflet of the diaphragm. Muscle strips were obtained from a similar position of each diaphragm to ensure a similar muscle fiber-type distribution between the muscle strips (Figure [1A](#F1){ref-type="fig"}). The isolated muscle strips were mounted in a contracting chamber filled with oxygenated Ringer's solution (121 mM NaCl, 21 mM NaHCO~3~, 11.5 mM glucose, 5.9 mM KCl, 2.0 mM CaCl~2~, 1.2 mM NaH~2~PO~4~, 1.0 mM MgCl~2~, and 0.9 mM Na~2~SO~4~; 21°C; pH 7.4) ([@B56]). Older mice were used in this study in order to simulate elderly or severe COPD patients who have suffered from extended periods of breathing difficulties due to diaphragm dysfunction and require the use of supplemental oxygen, granting clinical potentials of HPC in this population.

![**(A)** Schematic showing that two muscle strips were dissected out from each mouse diaphragm. Lines represent the position where the diaphragm was cut to make muscle strips. **(B)** Schematic showing hypoxia-reoxygenation protocol. Representative curves demonstrating the percentage of maximal force during reoxygenation. **(C)** Tg^+^ muscle vs. **(D)** Tg^+^ muscle + HPC.](fphys-09-01720-g001){#F1}

Muscle Function Experiment With Mediators
-----------------------------------------

In order to determine potential signaling mediators involved in the HPC pathway during reoxygenation, various inhibitors/activators were administered to muscle strips. The muscle strips were incubated in oxygenated Ringer's solution with respective inhibitors for 30 min prior to HPC treatment or equilibrium ([@B56]): antioxidants, *N*-acetyl cysteine (NAC; 1 mM; Sigma) and Tiron (O~2~^•−^ scavenger; 1 mM; Sigma) ([@B28]); PI3K inhibitor (LY294002; 100 μM; EMD Millipore Corporation) ([@B9]); Akt inhibitor (MK-2206; 50 μM; Selleck Chemicals) ([@B44]); ERK inhibitor (PD98059; 100 μM; Promega) ([@B42]); mPTP opener, carboxyatractyloside (CAR; 50 μM; Sigma) ([@B26]); mPTP opening inhibitor, cyclosporin A (100 μM; Cell Signaling Technology) ([@B37]); K~ATP~ channel opening inhibitor, glibenclamide (100 μM; Sigma) ([@B10]); and mitoK~ATP~ channel opener, diazoxide (100 μM; Sigma) ([@B10]) at 21°C. All inhibitors/mediators were prepared in DMSO except for antioxidants, NAC and Tiron, which were dissolved in deionized water according to manufacture's protocols. After 30 min of incubation, muscle strips were washed once and preserved in fresh Ringer's solution without the addition of drugs. The muscle strips were then subjected to HPC (alternating 2-min exposures of 95 N~2~-5% CO~2~ and 95% O~2~-5% CO~2~ for five times; 20 min total), in accordance with the previous study ([@B40]). These acute low oxygen (95% N~2~) and hyperoxic (95% O~2~ ∼722 mmHg) *ex vivo* conditions were utilized to ensure sufficient cellular levels of hypoxia and reoxygenation in our settings, which could have been affected by diffusion distance in the mouse diaphragm due to its thickness and potential leakage of gas from the non-sealed contraction chamber ([@B56]). For the two groups treated either with cyclosporin A or diazoxide, muscles were equilibrated in Ringer's solution bubbled with 95% O~2~-5% CO~2~ for 20 min instead of HPC. The Tg^+^ control group followed the same protocol in the absence of inhibitor (replaced by Ringer's solution) or HPC treatment (Figure [1B](#F1){ref-type="fig"}).

The muscle strips were then exposed to 30-min hypoxia (95 N~2~-5% CO~2~) followed by 15-min reoxygenation (95% O~2~-5% CO~2~). Continuous stimulation of muscle strips for 5 min to measure contractile force were introduced during 15--20 min of the hypoxic and 10--15 min of the reoxygenation periods (Figure [1B](#F1){ref-type="fig"}). Ringer's solutions were maintained at 37°C (normal human body temperature) during all muscle contraction measurements. Measured force was normalized by the maximal contraction during the equilibrium before HPC treatment and after 30-min incubation with mediators in order to minimize any potential confounding effects introduced by individual mice variations (Figure [1B](#F1){ref-type="fig"}). A myograph (model 800MS; Danish Myo Technology, Aarhus, Denmark) was used to measure muscle function, as described in the previous studies ([@B28]; [@B60]). Prior to initial testing, each muscle strip was stretched to attain maximal force of contractions using a mobile lever arm. Muscle contractile force was determined by a stationary force transducer (force range 0--1,600 mN), which was calibrated to convert electrical voltage to tension development per gram. The muscle was electrically stimulated (S48 stimulator, Grass Technologies, West Warwick, RI) with square-wave electrical pulses (0.2-ms pulse period, 250-ms train duration, 70 Hz, at 30 V). A converter (model ML826; AD Instruments, Colorado Springs, CO, United states) then translated these tetanic contractions into digital data for the interpretation in LabChart 7.3.7 analyzing software.

Statistics
----------

One-way ANOVA was used to analyze the data for statistical significance, and was expressed sequentially as means +/− SE (IBM SPSS Statistics 21). Post-ANOVA contrast analyses from IBM SPSS software was used to identify differences between treatments. *p* \< 0.05 was considered statistically significant for paired or independent sample *t*-tests, in comparison of same group samples or differing group samples, respectively. A sample size of five mice per group was determined using G^∗^Power version 3.1.6 that can provide 80% power to detect an effect size of 0.25 at a significance level of 0.05 based upon our previous data on wild-type mice.

Results
=======

As shown in Figures [1C,D](#F1){ref-type="fig"}, HPC treatment considerably reduced diaphragm muscle function decline during reoxygenation in Tg^+^ mice. Further, the percentage of maximal force in the Tg^+^ + HPC group was markedly higher than the Tg^+^ control group at each subsequent time point (0--5 min) during reoxygenation, suggesting that HPC improves muscle function (*n* = 5, *p* \< 0.01 for 1--5 min contraction; Figure [2](#F2){ref-type="fig"}).

![Averaged data illustrating the force decline during the 5-min contractile period under reoxygenation from muscles of Tg^+^ mouse (*n* = 6) vs. Tg^+^ mouse + HPC (*n* = 5). ^∗^Significant different from Tg^+^, *p* \< 0.05.](fphys-09-01720-g002){#F2}

Representative reoxygenation curves displaying the percentage of maximal contractile force with respective inhibitors/activators are depicted in Figure [3](#F3){ref-type="fig"}. The effects of HPC in improving muscle function were obliterated after incubation with (1) antioxidants (Tiron and NAC) in Figure [3C](#F3){ref-type="fig"}; (2) non-mitochondrial inhibitors (PI3K inhibitor, LY294002; ERK inhibitor, PD98059; AKT inhibitor, MK-2206) in Figures [3D--F](#F3){ref-type="fig"}; and (3) mitochondrial mediators (glibenclamide + carboxyatractyloside) in Figure [3I](#F3){ref-type="fig"}. Muscle strips incubated with either diazoxide or cyclosporin A individually demonstrated improved contraction force comparable to the HPC curve (Figures [3G,H](#F3){ref-type="fig"}, respectively). Diazoxide and cyclosporin A are potent mitoK~ATP~ channel opener and mPTP closer, respectively, which are both commonly used in studies investigating the signaling cascade underlying protection associated with ischemic preconditioning ([@B33]; [@B16]; [@B15]). Similarly, our previous study using diazoxide or cyclosporin A reported that HPC protective effects involve the closure of mPTP and the opening of mitoK~ATP~ channels in wild-type muscles ([@B56]). Our data show that both diazoxide and cyclosporin A treatment generates similar beneficial effects to that from HPC, suggesting the potential involvement of mitoK~ATP~ channel and mPTP in HPC-initiated effects.

![Representative reoxygenation curves showing percentage of force compared with baseline contraction of muscles incubated with respective inhibitors/activators. Data represent approximate average contractile curve for each condition. **(A)** Tg^+^ control; *n* = 6. **(B)** HPC; *n* = 5. **(C)** 1 mM Tiron (antioxidant) + 1 mM NAC (antioxidant) + HPC; *n* = 5. **(D)** 100 μM LY294002 (PI3K inhibitor) + HPC; *n* = 6. **(E)** 50 μM MK-2206 (Akt inhibitor) + HPC; *n* = 5. **(F)** 100 μM PD98059 (ERK inhibitor) + HPC; *n* = 5. **(G)** 100 μM diazoxide (K~ATP~ channel); *n* = 5. **(H)** 100 μM cyclosporin A (mPTP opening inhibitor); *n* = 5. **(I)** 100 μM gliben (K~ATP~ channel opening inhibitor) + 50 μM carb (mPTP opener) + HPC; *n* = 7. AKT, protein kinase B; Carb, carboxyatractyloside; ERK, extracellular signal-regulated kinases; Gliben, glibenclamide; HPC, hypoxic preconditioning; K~ATP~, mitochondrial ATP-sensitive potassium channel; mPTP, mitochondrial permeability transition pore; NAC, *N*-acetyl cysteine; PI3K, phosphoinositide 3-kinase.](fphys-09-01720-g003){#F3}

Grouped data summarizing the percentage of the maximal force at initial and end contraction during reoxygenation with different inhibitors or mediators are displayed in Figures [4A,B](#F4){ref-type="fig"}. The results confirmed that the Tg^+^ muscles can be significantly strengthened during reoxygenation after treating with HPC (*n* = 5; *p* = 0.004 for the 1st contraction; *p* = 0.005 for the end contraction), diazoxide *n* = 5; *p* = 0.004 for the 1st contraction; *p* = 0.006 for the end contraction), or cyclosporin A (*n* = 5; *p* = 0.01 for the 1st contraction; *p* = 0.000 for the end contraction). In Figure [4B](#F4){ref-type="fig"}, exposure to either diazoxide or cyclosporin A alone produced similar significance in muscle function as HPC. The normalized initial and end contractile forces increased compared to the control (n = 5; *p* = 0.004 for the 1st contraction; *p* = 0.005 for the end contraction). Non-mitochondrial signaling inhibitors and mitochondrial mediators (glibenclamide + carboxyatractyloside) diminished HPC-induced improvement in muscle function (Figure [4](#F4){ref-type="fig"}). Notably, muscle treated with glibenclamide + carboxyatractyloside resulted in contractile force significantly lower than control (Figure [4B](#F4){ref-type="fig"}; *n* = 7, *p* = 0.024 for the 1st contraction; *p* = 0.009 for the end contraction).

![Grouped data displaying the decline in diaphragmatic force (fatigue) during the 15-min reoxygenation period from Tg^+^ control (*n* = 6); HPC (*n* = 5); **(A)** non-mitochondrial channel inhibitors \[1 mM Tiron (antioxidant) + 1 mM NAC (antioxidant) + HPC (*n* = 5); 100 μM LY294002 (PI3K inhibitor) + HPC (*n* = 6); 50 μM MK-2206 (Akt inhibitor) + HPC (*n* = 5); 100 μM PD98059 (ERK inhibitor) + HPC (*n* = 5)\]; and **(B)** mitochondrial channel mediators \[100 μM diazoxide (K~ATP~ channel, *n* = 5); 100 μM cyclosporin A (mPTP opening inhibitor, *n* = 5); 100 μM gliben (K~ATP~ channel opening inhibitor) + 50 μM carb (mPTP opener) + HPC (*n* = 7)\]. ^∗^Significantly different from control (*p* \< 0.05). Baseline contraction forces were measured before HPC treatment. AKT, protein kinase B; Carb, carboxyatractyloside; ERK, extracellular signal-regulated kinases; Gliben, glibenclamide; HPC, hypoxic preconditioning; K~ATP~, mitochondrial ATP-sensitive potassium channel; mPTP, mitochondrial permeability transition pore; NAC, *N*-acetyl cysteine; PI3K, phosphoinositide 3-kinase.](fphys-09-01720-g004){#F4}

Discussion
==========

Our *ex vivo* results show that diaphragm muscle function during reoxygenation was significantly improved after HPC treatment in aged Tg^+^ mice. Using specific inhibitors and mitochondrial mediators, we have identified the potential HPC pathways, which may involve the activation of ROS, PI3K, Akt, ERK, as well as the triggering of mitoK~ATP~ channel opening and mPTP closure.

Role of ROS in HPC
------------------

Our previous studies on wild-type mice have similarly shown that the diaphragmatic function can be significantly improved by HPC during reoxygenation ([@B61]; [@B57]). The development of muscle fatigue is known to be associated with ATP depletion, metabolic by-product (e.g., H^+^ and phosphate) accumulation, decreased myofibrillar Ca^2+^ sensitivity, and oxidative stress ([@B38]; [@B14]; [@B7]). Interestingly, ROS play biphasic roles in skeletal muscle function and are considered to be the major mediators of preconditioning ([@B62]; [@B18]). Specifically, studies have shown that the elevation of xanthine oxidase (XO) contributes greatly to reoxygenation-associated ROS accumulation ([@B32]; [@B29]). An overproduction of ROS is considered as one of the contributors of reduced muscle function and it results in lipid peroxidation and oxidative alteration of cellular proteins thereby leading to reoxygenation injury ([@B39]; [@B23]; [@B63]). Optimal levels of ROS are involved in the intracellular adaptations and protection of various tissues by preconditioning ([@B6]; [@B62]). Our previous data on wild-type mice showed that HPC abolished the increase in ROS production during hypoxia and reoxygenation ([@B58], [@B56]). It is likely that this reduced level of ROS plays a key role in triggering the protective effect of HPC as well as lowering oxidative damage during reoxygenation. In the present study, ROS scavenging by the exogenous antioxidants, Tiron and NAC, attenuated the improved muscle function offered by HPC (Figures [3C](#F3){ref-type="fig"}, [4A](#F4){ref-type="fig"}), further implying the involvement of ROS in HPC protection.

PI3K-AKT-ERK Pathways in HPC
----------------------------

Moreover, in Tg^+^ mice models, diaphragmatic muscles treated with any of the cell signaling inhibitors of PI3K, Akt, and ERK showed diminished HPC effects (Figure [4A](#F4){ref-type="fig"}). Consistent findings were reported in other models such as cardiac progenitor cells, which suggest the pivotal role of PI3K, Akt, or ERK in hypoxic protection. For example, [@B52] observed that LY294002 (PI3K inhibitor) eliminates the pro-survival effect of HPC *in vitro*. Furthermore, in our study, 30-min incubation with the mediators did not alter the maximal muscle contractile force (data not shown), which suggests that the mediators used in our experiments did not have marked influence on muscle function in non-HPC treated muscles. In addition, Akt and ERK activation is beneficial to skeletal muscle by inducing increased ATP production, mitochondrial biogenesis, and functional adaptation, which is consistent with our result of HPC ([@B17]; [@B2]). Muscle contraction may increase glucose uptake via the activation of PI3K/Akt cascades in an insulin-dependent manner ([@B53]; [@B45]; [@B41]). In the absence of insulin, PI3K/Akt signaling was probably kept deactivated. However, HPC may activate PI3K/AKT independent of insulin, which stimulate glucose uptake ([@B43]) or regulate downstream mitochondrial channels to enhance the muscle function. Previous studies on the ERK involvement in muscle contraction have been focused on muscle adaptive responses to exercise or hypoxia via the upregulation of nuclear factor-κB (NF-κB) ([@B31]; [@B1]; [@B18]). Our data show that ERK inhibition reduced HPC-treated muscle function during reoxygenation, which suggests an acute effect mediated by ERK activation in HPC-induced muscle cell protection.

MitoK~ATP~ and MPTP in HPC
--------------------------

Our previous study showed that HPC induces both the closure of mPTP and the opening of mitoK~ATP~ channels in wild-type muscles ([@B56]). Similar results were observed in Tg^+^ muscles. Research has shown that abrupt mPTP opening, in response to oxidative stress and mitochondrial Ca^2+^ overload, is evident at the onset of reperfusion ([@B20]; [@B12]). The application of carboxyatractyloside to prevent mPTP closure may exacerbate the mPTP-induced cell injury. This may explain why HPC muscles incubated with carboxyatractyloside and glibenclamide showed significant lower muscle function than control muscles during reoxygenation (Figure [4B](#F4){ref-type="fig"}). The suppression of mPTP is crucial to retain mitochondrial integrity and prevent cell death ([@B20]; [@B4]). Moreover, previous evidence has shown that mitoK~ATP~ channel opening can be significantly activated in ischemic heart, indicating their critical roles in muscle protection under stress ([@B54]). Our data suggests that HPC may be able to enhance such protective effects associated with mitoK~ATP~ channel openings. ROS generated due to the activation of mitoK~ATP~ channels are reported to trigger preconditioning ([@B22]). It was reported that the reduction of mitoK~ATP~ channel opening is associated with the extent of fatigue ([@B13]). In addition, mitoK~ATP~ channel openings have been shown to lead to K^+^-specific mitochondrial depolarization and swelling of de-energized mitochondria in rat skeletal muscles, thereby modulating oxidative phosphorylation ([@B37]).

Limitations
-----------

There are a few limitations in this study. First, due to the need for continuous contraction, the diaphragm has high oxidative enzyme activities, giving it greater resistance to fatigue compared to other respiratory muscles ([@B36]). Despite altered fiber distribution and slow energy consumption, the diaphragm of COPD subjects produces similar isometric forces as non-COPD subjects, suggesting that the active cross-bridges generate greater force than those of control muscle ([@B35]; [@B48]). Second, overexpressed TNF-α can elevate ROS production, likely contributing to HPC-related molecular alterations ([@B25]). Thus, our future studies will directly determine the correlations between TNF-α levels and HPC effects. Third, diaphragm was kept at Ringer's solution bubbled with 95% O~2~ after isolation. However, this operation can cause additional reoxygenation-related muscle damage. The diaphragmatic muscles were stimulated for 5 min during both hypoxic and reoxygenation periods. This tetanic contraction during hypoxia is energetically expensive for muscles and can lead to additional fatigue or injury, thus affecting muscle performance during the following reoxygenation. All these limitations can possibly create some bias in the evaluation of reoxygenation-associated muscle function.

Perspectives and Significance
=============================

Little research has been focused on HPC or non-pharmacological treatments of respiratory skeletal muscle during reperfusion injuries and in the context of COPD in elderly. Here for the first time, we demonstrate that aged Tg^+^ (COPD-like) skeletal muscle which has undergone HPC sustains muscle force production and exhibits improved muscle function during reoxygenation. A possible signaling pathway involved in HPC protection has been proposed. Identifying the interaction between ROS, PI3K, Akt, ERK, and mitochondrial channels in HPC will be useful in developing pharmacological treatment that can enhance HPC effects. However, additional studies are needed to fully evaluate the clinical feasibility and effectiveness of HPC in different models.
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